European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure
Authors:
- Simona SaccoSSSimona Sacco
- Christian LamplCLChristian Lampl
- Faisal Mohammad AminFAFaisal Mohammad Amin
- Mark BraschinskyMBMark Braschinsky
- Christina DeligianniCDChristina Deligianni
- Derya UludüzDUDerya Uludüz
- Jan VersijptJVJan Versijpt
- Anne DucrosADAnne Ducros
- Raquel Gil-GouveiaRGRaquel Gil-Gouveia
- Zaza KatsaravaZKZaza Katsarava
- Paolo MartellettiPMPaolo Martelletti
- Raffaele OrnelloRORaffaele Ornello
Top Cited Papers
Open Access
- 12 October 2022
- journal article
- review article
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 23 (1) , 1-10
Abstract
Background: Triptans are migraine-specific acute treatments. A well-accepted definition of triptan failure is needed in clinical practice and for research. The primary aim of the present Consensus was to provide a definition of triptan failure. To develop this definition, we deemed necessary to develop as first a consensus definition of effective treatment of an acute migraine attack and of triptan-responder. Main body: The Consensus process included a preliminary literature review, a Delphi round and a subsequent open discussion. According to the Consensus Panel, effective treatment of a migraine attack is to be defined on patient well-being featured by a) improvement of headache, b) relief of non-pain symptoms and c) absence of adverse events. An attack is considered effectively treated if patient’s well-being, as defined above, is restored within 2 hours and for at least 24 hours. An individual with migraine is considered as triptan-responder when the given triptan leads to effective acute attack treatment in at least three out of four migraine attacks. On the other hand, an individual with migraine is considered triptan non-responder in the presence of failure of a single triptan (not matching the definition of triptan-responder). The Consensus Panel defined an individual with migraine as triptan-resistant in the presence of failure of at least 2 triptans; triptan refractory, in the presence of failure to at least 3 triptans, including subcutaneous formulation; triptan ineligibile in the presence of an acknowledged contraindication to triptan use, as specified in the summary of product characteristics. Conclusions: The novel definitions can be useful in clinical practice for the assessment of acute attack treatments patients with migraine. They may be helpful in identifying people not responding to triptans and in need for novel acute migraine treatments. The definitions will also be of help in standardizing research on migraine acute care.Keywords
This publication has 37 references indexed in Scilit:
- Why pharmacokinetic differences among oral triptans have little clinical importance: a commentThe Journal of Headache and Pain, 2010
- Elevated Saliva Calcitonin Gene‐Related Peptide Levels During Acute Migraine Predict Therapeutic Response to RizatriptanHeadache: The Journal of Head and Face Pain, 2009
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009
- The Phe‐124‐Cys and A‐161T Variants of the Human 5‐HT 1B Receptor Gene Are Not Major Determinants of the Clinical Response to SumatriptanHeadache: The Journal of Head and Face Pain, 2007
- Infrequent or Non-Response to Oral Sumatriptan does not Predict Response to Other Triptans—Review of Four TrialsCephalalgia, 2006
- Coronary Vasoconstrictor Potential of Triptans: A Review of In Vitro Pharmacologic DataHeadache: The Journal of Head and Face Pain, 2004
- Advances in pharmacological treatment of migraineExpert Opinion on Investigational Drugs, 2001
- Triptans in MigraineDrugs, 2000
- Zolmitriptan Provides Consistent Migraine Relief when Used in the Long TermCurrent Medical Research and Opinion, 1999
- The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and catsAnnals of Neurology, 1993